Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Metastatic Colorectal Cancer
Related studies linked through entity extraction aliases.
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy
- Status
- UNKNOWN
- Phase
- PHASE2
Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- NA
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
- Status
- COMPLETED
- Phase
- N/A
Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments
- Status
- COMPLETED
- Phase
- PHASE1
Sym004 in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
- Status
- TERMINATED
- Phase
- PHASE2
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
- Status
- COMPLETED
- Phase
- PHASE3
MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.
- Status
- UNKNOWN
- Phase
- PHASE2
Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring
- Status
- COMPLETED
- Phase
- N/A
Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
- Status
- COMPLETED
- Phase
- N/A
Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients
- Status
- COMPLETED
- Phase
- PHASE3
Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2